We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Unreliable Microarray Probes Hamper Research

By Biotechdaily staff writers
Posted on 14 Sep 2004
Molecular biologists who were concerned about the poor reproducibility of results in their field evaluated commercially available microarray biochips and found that greater than 19% of the probes on each platform did not correspond to their appropriate mRNA reference sequence (RefSeq)

The Reference Sequence (RefSeq) database provides a biologically nonredundant collection of DNA, RNA, and protein sequences. More...
Each RefSeq represents a single, naturally occurring molecule from a particular organism. RefSeq standards serve as the basis for medical, functional, and diversity studies; they provide a stable reference for gene identification and characterization, mutation analysis, expression studies, polymorphism discovery, and comparative analyses.

RefSeqs are frequently based on the records of GenBank (NCBI, U.S. National Center for Biotechnology Information) but differ in that each RefSeq is a synthesis of information, not a piece of a primary research data in itself. Similar to a review article in the literature, a RefSeq is an interpretation by a particular group at a particular time. RefSeqs can be retrieved in several different ways: by searching the Entrez Nucleotide or Protein database, by BLAST (basic local alignment search tool) searching, by FTP (file transfer protocol), or through links from other NCBI resources.

Investigators at Harvard Medical School (Boston, MA, USA) and Washington University (St. Louis, MO, USA) inspected commercially available microarray biochips in order to assess the accuracy of individual probe sequences used to query gene expression. They reported in the August 2004 issue of Physiological Genomics that more than 19% of the probe sequences failed to perfectly correspond with the appropriate mRNA as defined by the reference sequence. Furthermore, and not surprisingly, they found that sequence-verified probes performed more consistently, and with higher accuracy, within replicates and across different versions of the technology.




Related Links:
National Center for Biotechnology Information
Harvard University
Washington University

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.